Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
7 januari, 2025
7 januari, 2025
Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
PR Newswire
WALTHAM, Mass., Jan. 7, 2025
WALTHAM, Mass. , Jan. 7, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger , Chief Executive Officer of Syndax, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 10:30 a.m. PT / 1:30 p.m. ET .
A live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com , where a replay of the event will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn .
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G

SOURCE Syndax Pharmaceuticals, Inc.

7 januari, 2025
Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
PR Newswire
WALTHAM, Mass., Jan. 7, 2025
WALTHAM, Mass. , Jan. 7, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger , Chief Executive Officer of Syndax, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 10:30 a.m. PT / 1:30 p.m. ET .
A live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com , where a replay of the event will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn .
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G

SOURCE Syndax Pharmaceuticals, Inc.

Analys
Analys
1 DAG %
Senast

OMX Stockholm 30
0,99%
(vid stängning)
Stockholmsbörsen
10 april, 17:46
Börsen lyfte efter fredstrevare – Saab föll
OssDsign
10 april, 16:21
Medicinteknikbolaget rasar 40% på vinstvarning
Boeing
10 april, 15:41
Bolagen bakom Artemis färd till månen
Plejd
10 april, 14:56
Plejd rusar efter rekordkvartal
OMX Stockholm 30
1 DAG %
Senast
3 109,90